DARA BioSciences, Inc. Announces New Officer and Director Appointments

    RALEIGH, N.C., March 25 /CNW/ -- DARA BioSciences(TM) (Nasdaq:   DARA)
announced today the appointment of John Didsbury, Ph.D. as President and Chief
Operating Officer.  Dr. Didsbury has served as DARA's Chief Scientific Officer
since November 2006.  Dr. Didsbury previously served as President and CEO of
Nuada Pharmaceuticals, Inc. Dr. Didsbury replaces Richard A. Franco, who
notified the Board of Directors on March 21, 2008 of his decision to resign.
    The Company also announced today the re-appointment of Steve Gorlin to
the Board of Directors and the appointment of Steve Gorlin and Thomas W.
D'Alonzo as Co-Chairmen of the Board of Directors.  Mr. Gorlin was a founder
of DARA and previously served as a director. Mr. Gorlin currently serves as
Chairman of the Board for NTC China and MiMedx, Inc. (OTC BB:  AYXC.OB) and is
a member of the board of Surgi-Vision, Inc.  From 1998 to 2003, Mr. Gorlin
served on the Business Advisory Council to The Johns Hopkins School of
Medicine and currently sits on the board of The Johns Hopkins Alliance for
Science and Technology Development.  Mr. D'Alonzo has served as a member of
DARA's Board since 2005, and has served as Chief Executive Officer and a
member of the Board of Directors of MiMedx, Inc.  He is also currently a
Director of Salix Pharmaceuticals, Inc. (NASDAQ:    SLXP), BioDelivery Sciences,
Inc. (NADSAQ: BDSI), Amarillo BioSciences, Inc. (OTCBB:  AMAR.OB), and
Plexigen, Inc.  Mr. Gorlin was re-appointed to the Board to fill a vacancy
created by Mr. Franco's resignation.
    Thomas D'Alonzo commented, "It is a pleasure to announce John's
appointment as President of DARA.  John has a deep understanding of the
science behind the drugs in DARA's pipeline in addition to experience running
a company.  We believe the combination of his talents as a scientist and a
leader make him ideally suited to assume the role of DARA's President.  At the
same time, we are deeply indebted to Richard Franco for his service to the
Company, particularly his leadership and skill in consummating the recent
merger with Point Therapeutics.  We wish Richard well in his future
    Mr. D'Alonzo also stated, "We are also pleased that Steve Gorlin has
agreed to re-join our Board.  Steve has recently been involved in time-
consuming projects for other companies, but has graciously agreed to return to
the DARA Board during this exciting period as we transition to Dr. Didsbury's
    Dr. Didsbury commented, "It is a privilege to assume the role of DARA's
President.  I'm excited about DARA's product pipeline and look forward to
leading the Company as it advances the development of drugs with the potential
to meaningfully improve the lives of patients suffering from ailments like
neuropathic pain, type 2 diabetes, and psoriasis.  Steve Gorlin brings a
wealth of industry knowledge and relationships with his return to the Board,
and we are fortunate to have Steve and Tom's leadership as Co-Chairmen to help
guide DARA's strategy and direction going forward."
    About DARA BioSciences, Inc.
    DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based
development-stage pharmaceutical company that acquires promising therapeutic
molecules and medical technologies directly or through investment in
established companies. DARA focuses its therapeutic development efforts on
small molecules from late preclinical development through phase 2 clinical
trials. DARA is developing a portfolio of therapeutic candidates for
neuropathic pain, metabolic diseases including type 2 diabetes, dyslipidemia
and dermatological disorders.  DARA has licensed promising drug development
candidates from Kirin Pharmaceuticals of Japan, Bayer Pharmaceuticals
Corporation, Massachusetts General Hospital and Nuada LLC.
    For more information please contact the Company at 919-872-5578 or visit
our web site at www.darabio.com.
    All statements in this news release that are not historical are forward-
looking statements within the meaning of the Securities Exchange Act of 1934
as amended. Such forward-looking statements are subject to factors that could
cause actual results to differ materially for DARA from those projected. Those
factors include risks and uncertainties relating to the company's ability to
develop and bring new products to market as anticipated, the current
regulatory environment in which the company develops and sells its products,
the market acceptance of those products, dependence on partner, successful
performance under collaborative and other commercial agreements, competition,
the strength of DARA's intellectual property, the intellectual property of
others and other risk factors identified in the documents DARA has filed, or
will file, with the Securities and Exchange Commission. Copies of DARA's
filings with the SEC may be obtained from the SEC Internet site at
http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward- looking statements
contained herein to reflect any change in DARA's expectations with regard
thereto or any change in events, conditions, or circumstances on which any
such statements are based. DARA BioSciences and the DARA logo are trademarks
of DARA BioSciences, Inc.

For further information:

For further information: John C. Thomas, Jr., Chief Financial Officer, 
+1-919-872-5578, or Lynn H. Morris, Sr. Manager, Investor Relations &
Corporate  Operations, +1-919-872-5578, both of DARA BioSciences Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890